BIIB vs DLX · P/E 21, rev $9.89B vs P/E 13, rev $499.3M
Biogen Inc (BIIB) versus Deluxe Corporation (DLX) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Deluxe Corporation (DLX) is a conglomerates company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported DLX revenue for 2026-06-30 was $499.3M. Net income was $19.1M. Revenue was down 7.2% from 2026-03-31 to 2026-06-30. DLX currently screens at market cap $709.7M and trailing P/E 12.7.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. DLX currently screens at market cap $709.7M and trailing P/E 12.7.
Not investment advice. Open the BIIB and DLX stock pages for the full models.
Not investment advice.